Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Pivikto 150mg Tablet
Pivikto 150mg Tablet is a medication used to treat specific types of breast cancer, including hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated advanced breast cancer, and metastatic breast cancer.
Uses of Pivikto 150mg Tablet
Pivikto 150mg Tablet is used for:
Treatment of HR-positive, HER2-negative, PIK3CA-mutated advanced breast cancer.
Administration in combination with hormonal anticancer therapies to improve treatment efficacy.
Benefits of Pivikto 150mg Tablet
Delays disease progression and improves progression-free survival in breast cancer patients.
Enhances the effectiveness of hormonal anticancer therapies.
Offers a regimen that can be taken orally with food, promoting convenience and patient adherence.
Mechanism of Action of Pivikto 150mg Tablet
Pivikto 150mg Tablet contains alpelisib, a selective inhibitor of PI3K-alpha, an enzyme involved in cancer cell growth and survival pathways. By blocking PI3K-alpha, alpelisib suppresses aberrant signaling in PIK3CA-mutated breast cancer cells, leading to reduced proliferation and increased sensitivity to hormonal therapies.